SGLT2 Inhibitor Safe for Kidneys in Hospitalized COVID Patients - Medpage Today

But trial may have been underpowered to see acute kidney injury differences

Taking sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) didn't hinder renal outcomes for patients hospitalized with COVID-19, according to a secondary analysis of the DARE-19 … [+4586 chars]

full article...